GOV.UK
9 updates about Ophthalmology
-
Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
Coadministration of a corticosteroid with an HIV-treatment-boosting agent may increase the risk of adrenal suppression due to a pharmacokinetic interaction.
-
Letters sent to healthcare professionals in April 2016
In April 2016, letters were sent regarding canagliflozin (Invokana▼, Vokanamet▼), BCR-ABL tyrosine kinase inhibitors, pomalidomide (Imnovid▼), and retigabine (Trobalt)
-
Latanoprost (Xalatan): increased reporting of eye irritation since reformulation
Advise patients to tell their health professional if they experience severe eye irritation.
-
Corticosteroids e-learning module launched
The new module helps clinicians understand how to identify, manage and avoid side effects when using corticosteroids.
-
Dorzolamide hydrochloride/timolol maleate (Cosopt) preservative-free eye drops: new pipette design
Old pipette design withdrawn after reported eye injuries.
-
Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery
Cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been reported in patients taking the atypical antipsychotics risperidone or paliperidone.
-
Retigabine (Trobalt▼): indication restricted to last-line use and new monitoring requirements
Reports of pigment changes in ocular tissue, skin, lips or nails.
-
Off-label intraocular use of recombinant tissue plasminogen activator
Risk of intraocular lens opacification.
-
Ecoflac infusion solutions: risk of air embolism
To avoid the risk of air embolism, these products should not be infused under pressure.